Gordon Haskett analyst Chuck Grom downgrades Target (NYSE:TGT) from Buy to Hold.
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
BioNTech SE (NASDAQ:BNTX, ", BioNTech", )))) and Duality Biologics (Suzhou) Co., Ltd. ("DualityBio") today announced that the U.S. Food and Drug Administration ("FDA") granted